Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fubotv Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.68 (market cap $39.89B), while Fubotv Inc trades at $10.32 (market cap $270.29M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 147.6× Fubotv Inc's market cap. Which is the better fit depends on your goals.
| ALNY | FUBO | |
|---|---|---|
Market Cap | $39.89B | $270.29M |
Sector | Health | Technology |
52-Week High | $491.22 | $54.72 |
52-Week Low | $278.09 | $8.09 |
Enterprise Value | $38.15B | $440.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FUBO stock trades at $9.18, down 3.57% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue reaching $1.62B in 2024 and a projected net income margin of 7.61% for 2025, while valuation ratios like P/E of 2.39 and P/S of 0.18 appear attractive. Recent news highlights the appointment of Alisa Bowen as CEO, bringing media industry experience.
The outlook is mixed; analyst consensus is a Buy with a $16.25 price target, but risks include persistent negative cash flows, high debt levels, and competitive pressures in streaming. Investor sentiment is cautious pending execution of the new leadership's strategy and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
